Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its ...

Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering ...

Therapeutics “initiated patient dosing in its exploratory PIPE-791 Phase 1b, randomized, double-blind, placebo-controlled, ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...

Kezar Life Sciences (NASDAQ:KZR – Get Free Report) is anticipated to release its earnings data before the market opens on ...

Tuberculosis remains one of the most lethal infectious diseases caused by a single pathogen. According to the latest global ...

The City of Richmond’s Economic Development Authority (EDA) has sold and transferred an 18-acre parcel to the developer of ...

Bristol Myers Squibb is levering Fulcrum Therapeutics out of its life. | Bristol Myers Squibb is levering Fulcrum ...

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial ...

State-owned construction firm PTPP announced Thursday that its Kalibaru Terminal Phase 1B project in Tanjung Priok Port had ...

Q4 2024 Earnings Call Transcript March 4, 2025 Rigel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.8, expectations were $0.3. Operator: Greetings, and welcome to Rigel ...

Raydient is the developer of the 24,000-acre Wildlight master-planned community and is a division of Rayonier Inc. It owns ...